Emergent BioSolutions (NYSE:EBS) Trading Down 5.7% – Should You Sell?

Shares of Emergent BioSolutions Inc. (NYSE:EBS) traded down 5.7% on Tuesday . The company traded as low as $9.22 and last traded at $9.28. 499,409 shares were traded during mid-day trading, a decline of 85% from the average session volume of 3,266,502 shares. The stock had previously closed at $9.84.

Analysts Set New Price Targets

Several research analysts have issued reports on EBS shares. Benchmark increased their price target on Emergent BioSolutions from $8.00 to $12.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. Rodman & Renshaw restated a “buy” rating and issued a $16.00 target price on shares of Emergent BioSolutions in a research note on Friday, September 13th. Finally, StockNews.com lowered shares of Emergent BioSolutions from a “buy” rating to a “hold” rating in a research report on Wednesday, November 20th.

Emergent BioSolutions Trading Down 5.8 %

The company has a market capitalization of $502.29 million, a PE ratio of -2.31 and a beta of 1.59. The stock has a fifty day moving average of $9.18 and a two-hundred day moving average of $8.48. The company has a current ratio of 2.88, a quick ratio of 1.47 and a debt-to-equity ratio of 1.30.

Hedge Funds Weigh In On Emergent BioSolutions

A number of institutional investors have recently added to or reduced their stakes in the company. Barclays PLC boosted its stake in shares of Emergent BioSolutions by 361.6% in the 3rd quarter. Barclays PLC now owns 39,308 shares of the biopharmaceutical company’s stock worth $329,000 after buying an additional 30,792 shares during the last quarter. Oak Hill Advisors LP purchased a new position in Emergent BioSolutions in the 3rd quarter worth approximately $9,296,000. Geode Capital Management LLC lifted its holdings in shares of Emergent BioSolutions by 4.6% in the third quarter. Geode Capital Management LLC now owns 581,958 shares of the biopharmaceutical company’s stock worth $4,861,000 after buying an additional 25,776 shares in the last quarter. Wellington Management Group LLP grew its position in shares of Emergent BioSolutions by 19.6% during the third quarter. Wellington Management Group LLP now owns 136,289 shares of the biopharmaceutical company’s stock valued at $1,138,000 after purchasing an additional 22,295 shares in the last quarter. Finally, State Street Corp raised its holdings in shares of Emergent BioSolutions by 864.7% during the 3rd quarter. State Street Corp now owns 1,911,327 shares of the biopharmaceutical company’s stock worth $15,960,000 after acquiring an additional 1,713,200 shares in the last quarter. Institutional investors own 78.40% of the company’s stock.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.